Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials

Lung Cancer

Volumn 76, Issue 2, 2012, Pages 222-227

  Treat, Joseph ^a   Scagliotti, Giorgio V ^b   Peng, Guangbin ^a   Monberg, Matthew J ^a   Obasaju, Coleman K ^a   Socinski, Mark A ^c  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Combined analysis; First line chemotherapy; Histology; Pemetrexed

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CONFIDENCE INTERVAL; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; VINBLASTINE;

EID: 84859420077     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.10.021     Document Type: Article

References (28)

1. Jemal A., Siegel R., Xu J., et al. Cancer Statistics, 2010. CA Cancer J Clin 2010.
2. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
3. Shepherd F.A. Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol 1993, 5:310-322.
4. Walling J. Chemotherapy for advanced non-small-cell lung cancer. Respir Med 1994, 88:649-657.
5. Kortsik C., Albrecht P., Elmer A. Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study. Lung Cancer 2003, 40:85-90.
6. Kosmidis P., Mylonakis N., Nicolaides C., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002, 20:3578-3585.
7. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
8. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
9. Hirsch F., Sperafico A., Novello S., et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008, 3:1468-1481.
10. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
11. Scagliotti G., Hanna N., Fossella F., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
12. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(9699):1432-1440.
13. Kubota K., Niho S., Enatsu S., et al. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study. J Thorac Oncol 2009.
14. Zinner R.G., Novello S., Peng G., et al. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. Clin Lung Cancer 2010, 11:126-131.
15. Ceppi P., Volante M., Saviozzi S., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.
16. Ozasa H., Oguri T., Uemura T., et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 2010, 101:161-166.
17. Schultz R.M., Patel V.F., Worzalla J.F., et al. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999, 19:437-443.
18. Scagliotti G.V., De Marinis F., Rinaldi M., et al. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol 2009, 4:1568-1571.
19. Trani L., Myerson J., Ashley S., et al. Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations. Lung Cancer 2010.
20. Treat J.A., Gonin R., Socinski M.A., et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 2010, 21:540-547.
21. Kaplan E., Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958, 53:457-481.
22. Cox D., Snell E. Analysis of binary data 1989, Chapman & Hall, London. 2nd ed.
23. Treat J., Edelman M.J., Belani C.P., et al. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Lung Cancer 2010.
24. Belani C., Brodowicz T., Peterson P., et al. Nonsquamous histology: a predictor of efficacy for pemetrexed treatment of non-small cell lung cancer (NSCLC). An analysis of phase III trials using treatment-by-histology interaction. Chicago Multidisciplinary Symposium in Thoracic Oncology 2008, [abstract].
25. Hoang T., Dahlberg S., Schiller J., et al. Does histology predict survival of advanced non-small cell lung cancer (NSCLC) treated with standard platin-based chemotherapy? Retrospective analysis of E1594. 13th World Conference on Lung Cancer: PD6.4.1 2009, [abstract].
26. Chansky K., Mack P., Crowley J., et al. Chemotherapy outcomes by histologic subtype of non-small cell lung cancer (NSCLC): analysis of the SWOG database for antimicrotubule (AMT)-platinum therapy. 13th World Conference on Lung Cancer: B2.7 2009, [abstract].
27. Patel J.D., Bonomi P., Socinski M.A., et al. Treatment rationale and study design for the POINTBREAK study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009, 10:252-256.
28. Zinner R.G., Saxman S., Peng G., et al. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small cell lung cancer of nonsquamous histology. Clin Lung Cancer 2010, 11(5):352-357.